M&A Deal Summary |
|
|---|---|
| Date | 2022-02-14 |
| Target | BioDelivery |
| Sector | Life Science |
| Buyer(s) | Collegium Pharmaceutical |
| Deal Type | Add-on Acquisition |
| Deal Value | 604M USD |
| Advisor(s) | Moelis & Co. (Financial) Goodwin Procter (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2002 |
| Sector | Life Science |
| Employees | 357 |
| Revenue | 631M USD (2024) |
Collegium Pharmaceutical provides specialty pharmaceutical services by developing and planning to commercialize next-generation, abuse-deterrent products for patients suffering from chronic pain. Collegium Pharmaceutical was founded in 2002 and is based in Stoughton, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 3 |
| Sector: Life Science M&A | 2 of 3 |
| Type: Add-on Acquisition M&A Deals | 1 of 2 |
| State: North Carolina M&A | 1 of 2 |
| Country: United States M&A | 2 of 3 |
| Year: 2022 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-02-06 |
Assertio Therapeutics - NUCYNTA
California, United States Assertio Therapeutics, Inc. - NUCYNTA is a strong prescription pain medicine that contains an opioid (narcotic) that is used to manage short-term (acute) pain in adults when other pain treatments, such as non-opioid pain medicines, do not treat your pain well enough or you cannot tolerate them. |
Buy | $375M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-07-29 |
Ironshore Therapeutics
Morrisville, North Carolina, United States Ironshore Therapeutics is a pharmaceutical company providing patient-focused treatment options to improve the lives of patients and caregivers. Ironshore Therapeutics is based in Morrisville, North Carolina. |
Buy | $525M |
